| Biomarker ID | 584 |
| PMID | 21266523 |
| Year | 2011 |
| Biomarker | SLCO1B1; SLCO1B3; SLCO2A1; SLCO3A1; |
| Biomarker Basis | Expression Based |
| Biomolecule | mRNA |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated in CRPC metastases: SLCO1B1 (5.5 fold); SLCO1B3( 3.6 fold); SLCO2A1 (3.2 fold); SLCO3A1 (5.4 fold); |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways Include(SLCO1B1):- Recycling of bile acids and salts,Transport of organic anions,Transport of vitamins, nucleosides, and related molecules,Bile acid and bile salt metabolism,Codeine and morphine metabolism,Transport of vitamins, nucleosides, and related molecules,SLC-mediated transmembrane transport Pathways Include(SLCO1B3):-Transport of organic anions,Recycling of bile acids and salts,Bile acid and bile salt metabolism |
| Experiment | CRPC metastases versus untreated prostate cancer |
| Type of Biomarker | Prognostic |
| Cohort | Total of 1309 patients were undertaken for this study. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.053 |
| Method Used | qRT-PCR |
| Clinical | No |
| Remarks | Only caucasian patients were included in the analysis |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | SLCO1B1, SLCO1B3, SLCO2A1, SLCO3A1 |